Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Relapsed/Refractory Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled14 locationsNCT06714591
Recruiting
Phase 1

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences124 enrolled7 locationsNCT06549790
Recruiting
Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 1

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Hemogenyx Pharmaceuticals LLC18 enrolled1 locationNCT06786533
Recruiting
Phase 2

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)
Peking University People's Hospital56 enrolled1 locationNCT06869265
Recruiting
Early Phase 1

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541444
Recruiting
Early Phase 1

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541405
Recruiting
Phase 2

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Changzhou Qianhong Bio-pharma Co., Ltd.53 enrolled10 locationsNCT06532058
Recruiting
Phase 1

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)
Nanjing Chia-tai Tianqing Pharmaceutical72 enrolled1 locationNCT06049667